Abstract: The present invention is generally related to the prevention of leishmaniasis in animals, particularly infection caused by Leishmania sp., based on the use of Leishmania infantum P36 protein or an immunogenic fragment of the latter, or involving an expression system for the mentioned protein or fragment—optionally in combination with a compound stimulating the production of a Th1-type cellular immune response—and comprising various vaccination protocols in application to Leishmania sp. based on the mentioned vaccine.

Abstract: The present invention relates to a new isolate of Neospora caninum and to the extracts which may be produced therefrom. Said isolate presents a high degree of attenuation, which makes it suitable for the development of vaccines against neosporosis, and of diagnostic tests to detect infection by Neospora caninum in animals. It also describes pharmaceutical compositions wherein said isolate or extracts thereof are used for the prevention and treatment of the infections caused by Neospora caninum in animals.

Abstract: The present invention relates to Haemophilus parasuis polynucleotides produced by recombinant technology. It also relates to polypeptides that are expressed by said polynucleotides and also to a vaccine against H. parasuis that comprises said polypeptides. In another aspect, the invention also relates to the use of polynucleotides to determine if a strain of H. parasuis is virulent or avirulent.

Abstract: The present invention provides a method for obtaining an immunogenic, non-haemolytic strain of Actinobacillus pleuropneumoniae which is modified, at least in a segment of the apxIA gene and optionally in a segment of the apxIIA gene that encodes a transmembrane domain of the Apx haemolytic and cytolytic exotoxins. It comprises also the strains, and the attenuated live vaccine porcine pleuorpneumonia obtained therewith.

Abstract: The present invention relates to the gene of transferrin-binding protein 1 (Tbp1) of Actinobacillus pleuropneumoniae, its use to prepare products for vaccination against porcine pleuropneumonia and as diagnostic reagents. The invention also relates to the use of Tbp1 or fragments thereof to produce monoclonal or polyclonal antibodies to be used in diagnostic kits. The invention also relates to the use of Tbp1 or fragments thereof, alone or combined to other virulence factors of the pathogen, as vaccination products against porcine pleuropneumonia.